2016
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial
Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives Of Pathology & Laboratory Medicine 2016, 140: 66-74. PMID: 26717057, DOI: 10.5858/arpa.2014-0599-oa.Peer-Reviewed Original ResearchConceptsHazard ratioBreast cancerResidual riskMultivariate Cox proportional hazardsDistant recurrence-free survivalClinical prognostic factorsEarly breast cancerRecurrence-free survivalSignificant prognostic valueCox proportional hazardsHER2/neuIHC4 scoreHormone therapyNodal statusTrial cohortPrognostic factorsPrognostic valueClinical trialsKi-67Proportional hazardsMultivariate analysisTEAM trialBiomarker expressionQuantitative immunofluorescenceResidual risk assessment
2014
Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research 2014, 20: 5995-6005. PMID: 25255793, PMCID: PMC4252785, DOI: 10.1158/1078-0432.ccr-14-1622.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD20Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCD3 ComplexCD8 AntigensChemotherapy, AdjuvantFemaleHumansImmunophenotypingLymphocyte SubsetsLymphocytes, Tumor-InfiltratingMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingPrognosisReproducibility of ResultsTreatment OutcomeTumor BurdenConceptsTumor-infiltrating lymphocytesPathologic complete responseBreast cancerTonsil specimensPredictive valueAQUA scoreQuantitative immunofluorescenceFlow cytometryFuture larger studiesPathologist estimationNeoadjuvant cohortNeoadjuvant chemotherapyNeoadjuvant therapyLymphocyte infiltratesTIL countComplete responseNodal statusLymphocyte percentageLymphocyte subpopulationsStromal expressionNuclear gradeUnivariate analysisKi-67CD8Clinical utility
2013
Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.
Brown J, Lannin D, Killelea B, DiGiovanna M, Rimm D. Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2013, 31: 1085-1085. DOI: 10.1200/jco.2013.31.15_suppl.1085.Peer-Reviewed Original ResearchKi-67 expressionPathological complete responseNeoadjuvant chemotherapyKi-67Consecutive invasive breast cancer patientsAQUA scoreInvasive breast cancer patientsAdditional survival benefitBreast cancer patientsKi-67 levelsPre-surgical biopsyKi-67 scoreLikelihood of responseMIB-1 antibodyPrediction of responseNeoadjuvant therapyComplete responseNodal statusSurvival benefitER statusIndependent predictorsMultivariable analysisAdvanced tumorsTumor sizeCancer patients
2009
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg BE, Bracken MB, Rimm DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2009, 101: 452-474. PMID: 19318635, PMCID: PMC2720709, DOI: 10.1093/jnci/djp038.Peer-Reviewed Original ResearchConceptsCohort studyCutaneous melanomaMelanoma cell adhesion moleculeSystematic reviewEarly-stage cutaneous melanomaPotential prognostic valueMatrix metalloproteinase-2Cell nuclear antigenREMARK criteriaAdjuvant therapyMultivariable analysisREMARK guidelinesRisk stratificationPrognostic valueSurvival outcomesIncomplete adherenceMelanoma outcomesClinical managementImmunohistochemical expressionCell adhesion moleculeInclusion criteriaKi-67Tissue biomarkersClinical practiceMetalloproteinase-2
2006
Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Research 2006, 66: 5487-5494. PMID: 16707478, DOI: 10.1158/0008-5472.can-06-0100.Peer-Reviewed Original ResearchConceptsProgesterone receptorEstrogen receptorPrognostic valueBreast cancerKi-67X-tile softwareProportional hazards modelBreast cancer prognosisBreast cancer showBreast cancer tumorsΒ-catenin expressionYale Pathology archivesHazard ratioNode statusPoor outcomeTumor sizePrognostic markerWorse outcomesImmunohistochemical studyNuclear gradeCase cohortLow-level expressionPathology archivesTissue microarrayBeta-catenin expression
2005
Immunohistochemical Biomarkers in Patients with Early-Onset Breast Carcinoma by Tissue Microarray
Choi DH, Kim S, Rimm DL, Carter D, Haffty BG. Immunohistochemical Biomarkers in Patients with Early-Onset Breast Carcinoma by Tissue Microarray. The Cancer Journal 2005, 11: 404-411. PMID: 16259871, DOI: 10.1097/00130404-200509000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAdultBiomarkers, TumorBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryKi-67 AntigenMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasms, Ductal, Lobular, and MedullaryProtein Array AnalysisProto-Oncogene Proteins c-bcl-2Receptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTime FactorsTumor Suppressor Protein p53Women's HealthConceptsHER-2/neuBreast cancerProgesterone receptorKi-67Local relapseNodal statusYoung womenDistant metastasisTumor stageBiologic markersEstrogen receptorRelapse-free survival rateDistant metastasis-free rateDistant relapse-free survival ratesEarly-stage breast cancerEarly-onset breast cancerEarly-onset breast carcinomaProgesterone receptor negativityGroup of patientsMetastasis-free rateBcl-2Ki-67 positivityParaffin-embedded specimensTissue microarray methodConservative surgery
2004
Long-term preservation of antigenicity on tissue microarrays
DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Laboratory Investigation 2004, 84: 1071-1078. PMID: 15195116, DOI: 10.1038/labinvest.3700131.Peer-Reviewed Original Research